Avanos Medical, Inc. filings document the regulatory record of a medical technology company with product portfolios in Specialty Nutrition Systems and Pain Management and Recovery. Current reports furnish operating results, segment performance, investor presentations, material definitive agreements, executive compensation actions and organizational restructuring disclosures.
Proxy materials describe annual meeting matters, board elections, governance practices and compensation programs. The filings also cover capital-structure disclosures, shareholder voting matters, product-portfolio descriptions for enteral feeding and non-opioid pain therapies, and formal exhibits tied to material events.
Avanos Medical, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 2,000,000 shares of common stock, representing 4.30% of the class. The filing states Armistice Capital, as investment manager to the Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over those shares. The Master Fund is the direct holder and disclaims direct beneficial ownership due to its investment management agreement with Armistice Capital. The joint filing is signed by Steven Boyd on May 15, 2026.
BLACKFORD GARY reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Gary Blackford received a grant of 12,003 restricted share units on May 8, 2026. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The 12,003 restricted share units were issued to replace units originally granted on January 2, 2025 and will vest when Blackford terminates his service on the company’s Board of Directors.
Egbuonu-Davis Lisa reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical, Inc. director Lisa Egbuonu-Davis received a grant of 12,003 restricted share units on May 8, 2026. Each unit provides a contingent right to a cash payment equal to the value of one share of Avanos common stock.
The new restricted share units fully replace an earlier grant made on January 2, 2025. These units vest when Egbuonu-Davis terminates her service on the company’s Board of Directors. After this grant, she holds 12,003 restricted share units directly as reported in this filing.
Franchini Indrani Lall reported acquisition or exercise transactions in this Form 4 filing.
Avanos Medical director Indrani Lall Franchini received a grant of 12,003 restricted share units on May 8, 2026. These units are a cash-settled award, each representing a contingent right to receive a payment equal to the value of one share of Avanos common stock.
The new 12,003 restricted share units replace a prior grant originally issued on January 2, 2025. The units vest when Franchini terminates her service on Avanos Medical’s Board of Directors, aligning the award with her continued board tenure rather than short-term performance.
OLEARY PATRICK J reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Patrick J. O’Leary received a grant of 12,003 restricted share units on May 8, 2026 as compensation. Each unit represents a contingent right to a cash payment equal to the value of one share of Avanos common stock.
These units were issued to replace restricted share units originally granted on January 2, 2025. The award vests when O’Leary’s service on the company’s Board of Directors ends, meaning the units are long-term, service-based compensation rather than an immediate cash payout.
Shimer Julie Ann reported acquisition or exercise transactions in this Form 4 filing.
AVANOS MEDICAL, INC. director Julie Ann Shimer reported a compensation-related grant of 12,003 restricted share units on May 8, 2026. Each unit is a contingent right to receive a cash payment equal to the value of one share of Avanos common stock.
These restricted share units were issued to replace units originally granted on January 2, 2025, and will vest when Shimer terminates her service on the company’s Board of Directors. Following this award, she holds 12,003 restricted share units directly.
T. Rowe Price Investment Management, Inc. filed Amendment No. 5 to a Schedule 13G/A reporting beneficial ownership of 1,703,510 shares of Avanos Medical Inc. common stock, representing 3.7% of the class as of 04/30/2026. The filer states it owns 5% or less and disclaims beneficial ownership in the filing.
Avanos Medical Inc. ownership update: T. Rowe Price Investment Management reports beneficial ownership of 5,330,776 shares of Common Stock, representing 11.5% of the class as of 03/31/2026. The filing amends prior disclosures and notes that T. Rowe Price Small-Cap Value Fund holds 2,839,254 shares (6.1%).
Avanos Medical reported first-quarter 2026 results and outlined a pending cash merger that will take the company private. Net sales rose to $182.2 million from $167.5 million, driven mainly by Specialty Nutrition Systems, while net income declined to $5.1 million from $6.6 million, or $0.11 per diluted share.
Specialty Nutrition Systems revenue grew to $124.0 million, including contributions from the 2025 Nexus acquisition, while Pain Management and Recovery was roughly flat at $56.3 million. Operating income was $8.9 million, and adjusted operating income was $16.2 million, reflecting restructuring and acquisition-related costs.
Cash and equivalents were $65.6 million and term loan debt was $98.4 million, with operating activities using $12.3 million of cash in the quarter. A restructuring plan tied to the 2023 Respiratory Health divestiture has generated $43.1 million of cumulative expenses and is expected to run through 2026.
After quarter-end, Avanos agreed to be acquired by affiliates of American Industrial Partners for $25.00 per share in cash, with all shares and equity awards to be cashed out at closing. The transaction requires shareholder approval and regulatory clearances and, if completed, will result in Avanos being delisted from the New York Stock Exchange.
Avanos Medical, Inc. reported first quarter 2026 results and highlighted a pending acquisition by affiliates of American Industrial Partners in an all-cash transaction valuing the company at an enterprise value of $1.272 billion.
For the quarter, net sales were $182.2 million, up 8.8% from $167.5 million a year earlier, driven by double-digit organic growth in the Specialty Nutrition Systems segment. Net income was $5.1 million versus $6.6 million last year, with diluted EPS of $0.11 compared to $0.14. Adjusted net income was $10.6 million and adjusted diluted EPS $0.22, down from $12.0 million and $0.26.
Specialty Nutrition Systems net sales rose to $124.0 million, while Pain Management & Recovery net sales were $56.3 million and roughly flat year over year, with that segment moving to an operating loss of $1.8 million. Adjusted EBITDA was stable at $21.8 million versus $21.6 million.
Cash used in operating activities was $12.3 million, compared with cash provided of $25.7 million in the prior-year quarter. Free cash flow was an outflow of $16.6 million versus an inflow of $19.0 million. Cash and cash equivalents were $65.6 million as of March 31, 2026, with total debt of $98.2 million on the term loan facility.